Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, today announces promising surgeon feedback from the first
completed cases utilizing its new CATALYSTEM Primary Hip System.
Designed to address the evolving demands of primary hip surgery -
including the increased adoption of anterior approach procedures –
the CATALYSTEM Primary Hip System features a triple-taper stem
design with uniform proximal loading.1 The reduced distal
stem geometry and shorter lengths are ideal for anterior approach
but suitable for all approaches.2
The first surgical procedures using the CATALYSTEM Primary Hip
System were completed last week in the United States by three
prominent orthopaedic surgeons who commented on their experience
utilizing the system for the first time.
“Smith+Nephew’s new CATALYSTEM Primary Hip System with RI.HIP
NAVIGATION represents the beginning of a new era combining advanced
technology and patient personalization that will, without doubt,
enhance patient outcomes,” said Dr. Thorsten Seyler of Duke
University.
The CATALYSTEM Primary Hip System also utilizes proprietary,
patent-pending, ACCUBROACH◊ Technology delivering
proven reproducibility between broach and implant giving confidence
in predictable and reproducible stem seating.3,4
“The instruments were exceptionally user-friendly and ideal for
the direct anterior approach,” commented George Haidukewych MD,
Orlando Health, Orlando, Florida. “The broaches showed a
significant improvement in performance, offering superior cutting
and a more precise feel for rotational stability. In comparison to
other implants I've used in recent years, these stand out as
markedly better. Overall A-plus…it could not have gone better.”
Dr. Ran Schwarzkopf, Orthopedic Adult Hip and Knee
Reconstruction Surgeon at NYU Langone Health commented, "The case
went smoothly and exceeded all my expectations. It's the best
anatomically fitting stem I've ever seen - it fit the patient's
anatomy perfectly. The advantage of the broaches giving exact
stem-to-broach positioning is unmatched in the industry.”
To learn more about Smith+Nephew’s new CATALYSTEM Primary Hip
System for total hip arthroplasty, please visit
https://www.smith-nephew.com/en/health-care-professionals/products/orthopaedics/catalystem
- ends –
Media EnquiriesDave Snyder
+1 (978)
749-1440 Smith+Nephew
david.snyder@smith-nephew.com
References
- Smith + Nephew 2024. Finite Element Analysis of the CATALYSTEM
Hip Stem Design. Internal Report. OR-24-025
- Smith + Nephew 2024. Surgeon Feedback on the CATALYSTEM Total
Hip System. Internal Report. CSD.REC.24.001
- Smith + Nephew 2024. Cadaveric study of the repeatability of
CATALYSTEM broach and femoral stem seating level. Internal Report.
10144794
- Smith + Nephew 2024. CATALYSTEM Accubroach Femur to Bone
Interaction Design Rationale. Internal Report. 10142827
This document is provided for informational purposes and is not
intended to serve as medical advice. It is the responsibility
of healthcare professionals to determine and utilise the
appropriate products and techniques according to their own clinical
judgment for each of their patients.
The surgeon testimonials set out in this document represent the
individual surgeon’s opinions, findings, beliefs, and/or
experiences. Individual results will vary. The surgeons
featured were involved in the development of CATALYSTEM and were
compensated by Smith+Nephew for their time.
To review the information needed to understand and use
CATALYSTEM safely and effectively, including indications for use,
contraindications, effects, precautions, and warnings, please
consult the product’s applicable Instructions for Use (IFU) prior
to use.
Products featured may not be available in individual markets due
to regulatory and/or medical practices. Please contact your
Smith+Nephew representative if you have questions about
availability of Smith+Nephew products in your area.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading profit margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: conflicts
in Europe and the Middle East, economic and financial conditions in
the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and
innovative medical devices; developments in medical technology;
regulatory approvals, reimbursement decisions or other government
actions; product defects or recalls or other problems with quality
management systems or failure to comply with related regulations;
litigation relating to patent or other claims; legal and financial
compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of
our suppliers; competition for qualified personnel; strategic
actions, including acquisitions and disposals, our success in
performing due diligence, valuing and integrating acquired
businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to
market developments; relationships with healthcare professionals;
reliance on information technology and cybersecurity; disruptions
due to natural disasters, weather and climate change related
events; changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC’s website at www. sec.gov, for
a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
Smith and Nephew (NYSE:SNN)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Smith and Nephew (NYSE:SNN)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
